Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells A case report
Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells A case report
复制标题
DOI：
10.1097/md.0000000000021429
复制
发表时间：
2020-07-31
期刊：
影响因子：
1.6
通讯作者：
Hu, Min
中科院分区：
文献类型：
--
作者：
Liang, Bing;Chen, Junhui;Hu, Min
理由：2020年1月和2月，新冠肺炎案件增长非常快。危重病人尤其是老年病人的死亡率相对较高。考虑到许多患者死于严重的炎症反应，迫切需要为这些患者制定有效的治疗策略。人脐带间充质干细胞(HUCMSCs)具有良好的免疫调节和修复损伤组织的能力。因此，有必要研究脐血间充质干细胞在新冠肺炎危重患者救治中的应用潜力。患者关注：一名65岁的妇女感到疲惫，发烧，体温38.2摄氏度，咳出白色泡沫痰。1天后出现胸闷，SpO(2)达81%，血压160/91 mm Hg。诊断：根据《2019年新型冠状病毒感染肺炎诊疗指南(试行4版)》，基于SARS-CoV-2实时荧光定量RT-PCR法对新冠肺炎进行诊断。干预：常规治疗12d后，患者炎症症状仍很严重，观察糖皮质激素的潜在副作用。然后，给予同种异体hUCMSCs 3次(每次5×10(7)个细胞)，间隔3d，同时每日注射胸腺肽α1和抗生素。结果：治疗后，大部分实验室指标和CT图像显示炎症症状缓解。患者随后被转出ICU，4天后咽拭子试验报告为阴性。教训：这些结果表明同种异体hUCMSCs移植的临床结果和良好的耐受性。
Rationale: The COVID-19 cases increased very fast in January and February 2020. The mortality among critically ill patients, especially the elder ones, is relatively high. Considering many patients died of severe inflammation response, it is urgent to develop effective therapeutic strategies for these patients. The human umbilical cord mesenchymal stem cells (hUCMSCs) have shown good capabilities to modulate the immune response and repair the injured tissue. Therefore, investigating the potential of hUCMSCs to the treatment of COVID-19 critically ill patients is necessary. Patient concerns: A 65-year-old woman felt fatigued and had a fever with body temperature of 38.2 degrees C, coughed up white foaming sputum. After 1 day, she had chest tightness with SPO(2)of 81%, and blood pressure of 160/91 mm Hg. Diagnose: According to the guideline for the diagnosis and treatment of 2019 novel coronavirus infected pneumonia (Trial 4th Edition), COVID-19 was diagnosed, based on the real-time RT-PCR test of SARS-CoV-2. Interventions: After regular treatment for 12 days, the inflammation symptom of the patient was still very severe and the potential side effects of corticosteroid were observed. Then, allogenic hUCMSCs were given 3 times (5 x 10(7)cells each time) with a 3-day interval, together with thymosin alpha 1 and antibiotics daily injection. Outcomes: After these treatments, most of the laboratory indexes and CT images showed remission of the inflammation symptom. The patient was subsequently transferred out of ICU, and the throat swabs test reported negative 4 days later. Lessons: These results indicated the clinical outcome and good tolerance of allogenic hUCMSCs transfer.